Day One: Tuesday, June 4, 2024Tuesday, 4 June 2024 - ET (Eastern Time, GMT-05:00)

This panel discussion aims to examine the implications of the APEC Biopharmaceutical and Medical Device Business Ethics Initiative for Canada. As a member of the Asia-Pacific Economic Cooperation (APEC), Canada holds a pivotal role in shaping ethical standards and practices within the biopharmaceutical and medical device industries across the region. The initiative seeks to foster a culture of integrity, transparency, and accountability in business conduct, addressing critical ethical challenges and promoting responsible corporate behavior. Our panel of experts will delve into the potential impact of this initiative on Canadian companies operating in the biopharmaceutical and medical device sectors, as well as its significance for regulatory frameworks and international collaborations. Through insightful discussions we will highlight the opportunities and challenges that the APEC Business Ethics Initiative presents for Canadian stakeholders, including industry leaders, Patients and Patient Organizations policymakers, and healthcare professionals. Join us to gain valuable insights into the evolving ethical landscape and its implications for Canada's biopharmaceutical and medical device business within the APEC region.

Senior-level compliance and legal panelists dive into current and emerging challenges, forward-facing initiatives and how to augment and future-proof your compliance strategy to ensure efficient and compliant operations.

Leaders from across the business discuss navigating interdepartmental communication and collaboration challenges, strategies to optimize organization-wide operations and each leader’s future outlook on the bio/pharmaceutical/MedTech industry.

• Hear from an HR executive panelist to explore the role of HR in various daily health care compliance activities, from conducting internal or externally-executed sensitive investigations

• Explore the role the HR function can play in ensuring the enterprise-wide prioritization of DE&I elements in these health care compliance activities

Convene with industry peers during this Think Tank session dedicated to exploring the complexities and industry impact of the incorporation of AI in life sciences, key considerations for manufacturers in the utilization of AI and machine learning and resultant risk areas and what you need to know to effectively harness AI and reduce risk.

• Industry Analysis
• Use Case/Case Study
• Emerging Risks
• Best Practices and Guiding Principles for Compliance and Legal

Hear from a business leader to gain an in-depth understanding of their pulse on the industry, including current business priorities, innovative business strategies and how to further business-compliance partnerships.

Gain industry perspective on the role and importance of RWE and understand developments permitting the use of RWE in drug advertising.

In this session, industry experts will navigate the ever-evolving landscape of compliance, identifying and analyzing the key risk areas that organizations must prioritize in the current regulatory environment. From emerging technologies to shifting global regulations, we'll explore the challenges and opportunities facing compliance professionals in the year ahead. Don't miss this essential discussion to stay ahead of the curve and safeguard your organization's integrity and reputation.

• Explore the role of the compliance officer in mergers and acquisitions

• Navigate compliance challenges faced in mergers and acquisitions and discuss key considerations and effective strategies in ensuring a streamlined transition